
UPDATED COVID-19 VACCINE SCHEDULES – 12/13/22




a. The previously authorized 3-dose Pfizer-BioNTech primary series for children ages 6 months-4 years has been revised as follows: a monovalent Pfizer-BioNTech vaccine is administered for the first and second doses, followed by 1 bivalent Pfizer-BioNTech vaccine as the third primary series dose, at least 8 weeks after the second monovalent primary series dose. A booster dose is not authorized for children in this age group who receive a Pfizer-BioNTech 3-dose primary series, including children previously received a 3-dose monovalent Pfizer-BioNTech primary series dose. A booster dose is not authorized for children in this age group who receive a Pfizer-BioNTech 3-dose primary series. b. An 8-week interval between the first and second primary series doses of Moderna, Novavax and Pfizer-BioNTech (OVID-19 vaccines may be optimal for some people ages 6 months-64 years, especially for males ages 12-39 years, as it may reduce the small risk of myocarditis associated with these vaccines. A shorter interval 6 years and primary series in the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

C. In general, the same COVID-19 monovalent vaccine product (Pfizer-BioNTech, Moderna, Novavas) should be used for all doses in the primary series. In exceptional situations when the previous product cannot be determined/not available or if a person is unable to complete a series with the same COVID-19 vaccine due to a contraindication any age-appropriate mRNA COVID-19 vaccine may be used (administer at a minimum interval of 28 days).

d. For bivalent booster vaccination, any homologous or heterologous age-appropriate mRNA vaccine can be used. Recommendations vary based on age and primary series product.

e. Monovalent boosters are no longer authorized for this age group



a. In general, the same COVID-19 monovalent vaccine product (Pfizer-BioNTech, Moderna, Novavax) should be used for all doses in the primary series. In exceptional situations when the previous product cannot be determined/not available or if a person is unable to complete a series with the same COVID-19 vaccine due to a contraindication any age-appropriate mRNA COVID-19 vaccine may be used (administer at a minimum interval of 28 days). b. An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months-64 years, especially for males ages 12-39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (3 weeks for Novavax and Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.


c. Monovalent boosters are no longer authorized for this age group.

d. For bivalent booster vaccination, any homologous or heterologous age-appropriate mRNA vaccine can be used. Recommendations vary based on age and primary series product

Updated: 12/13/22

Novavax COVID-19 Vaccination Schedule NDSU IMMUNIZATION RESEARCH AND EDUCATION






a. In general, the same COVID-19 monovalent vaccine product (Pfizer-BioNTech, Moderna, Novavax) should be used for all doses in the primary series. In exceptional situations when the previous product cannot be determined/not available or if a person is unable to complete a series with the same COVID-19 vaccine due to a contraindication any age-appropriate mRNA COVID-19 vaccine may be used (administer at a minimum interval of 28 days). b. For booster vaccination, any homologous or heterologous age-appropriate mRNA vaccine can be used. Recommendations vary based on age and primary series product. People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series if they are unable (i.e., contraindicated or not available) or unwilling to receive a monovalent Novavax booster dose.

c. Monovalent boosters are no longer authorized for this age group

Updated: 12/13/22

NDSU CENTER FOR IMMUNIZATION RESEARCH AND EDUCATION

Johnson & Johnson (Janssen) COVID-19 Vaccination Schedule



<u>ALERT:</u> Janssen (Johnson & Johnson) COVID-19 Vaccine should ONLY be used in certain limited situations. See the CDC's clinical considerations for greater detail: https://www.cdc.gov/vaccines/covid-19/clinical- considerations/interim-considerations-us-appendix.html#appendix-a

a. People who are moderately or severely immunocompromised ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive a second (additional) dose using a monovalent mRNA vaccine and 1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech). The primary series dose and the additional dose are separated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after the additional dose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. b. People ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive 1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech) at least 2 months after completion of the primary series dose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. c. Monovalent boosters are no longer authorized for this age group

For more information on COVID-19 vaccine schedules:

CDC Interim Clinical Considerations: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html

NDHHS COVID-19 Vaccine Information: https://www.hhs.nd.gov/public- health-information/coronavirus/covid-19-vaccine-information